ArticleTheranostics2018
Chemoresistance Transmission via Exosome-Mediated EphA2 Transfer in Pancreatic Cancer.
Open access · goldAbstract read
In one paragraph
Article in Theranostics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers.
0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed
4.4field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 140 citations in OpenAlex.
- Translation of a novel EphA2-targeted PET tracer from preclinical models to first-in-human studies in pancreatic cancer.European journal of nuclear medicine and molecular imaging · 2026Article
- Extracellular vesicle biomarkers in pancreatic ductal adenocarcinoma: from bulk detection to single-extracellular vesicle profiling and endoscopic liquid biopsy.Journal of gastroenterology · 2026Review
- Dual role of exosomes in pancreatic cancer: Underlying mechanisms and research advances (Review).Oncology letters · 2026Review
- Overcoming tumour resistance in cancer immunotherapy through predictive and pharmacodynamic biomarkers.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- EphA2 sustains the adaptive response of colorectal organoids to chemotherapy.Frontiers in cell and developmental biology · 2026Article
- Extracellular Vesicle-Mediated Regulation of H3C14 Contributes to Gemcitabine Resistance in Bladder Cancer.Journal of extracellular vesicles · 2025Article
- Engineered exosomes: a promising approach for overcoming challenges in pancreatic cancer therapy.Journal of nanobiotechnology · 2025Review
- Extracellular Vesicles for Clinical Diagnostics: From Bulk Measurements to Single-Vesicle Analysis.ACS nano · 2025Review
- Proteomics in pancreatic cancer.Biomarker research · 2025Review
- N6-methyladenosine RNA modified BAIAP2L2 facilitates extracellular vesicles-mediated chemoresistance transmission in gastric cancer.Journal of translational medicine · 2025Article
- Extracellular Vesicles as Mediators and Potential Targets in Combating Cancer Drug Resistance.Molecules (Basel, Switzerland) · 2025Review
- Role of Acorus calamus extract in reducing exosome secretion by targeting Rab27a and nSMase2: a therapeutic approach for breast cancer.Molecular biology reports · 2025Article
- Multi-omics dissection of tumor microenvironment-mediated drug resistance: mechanisms and therapeutic reprogramming.Frontiers in pharmacology · 2025Review
- Exosomes: their role and therapeutic potential in overcoming drug resistance of gastrointestinal cancers.Frontiers in oncology · 2025Review
- A machine-learning approach for pancreatic neoplasia classification based on plasma extracellular vesicles.Frontiers in oncology · 2025Article
- Exosome applications for the diagnosis and treatment of pancreatic ductal adenocarcinoma: An update (Review).Oncology reports · 2025Review
- Erythropoietin-induced hepatocyte receptor A2 regulates effect of pyroptosis on gastrointestinal colorectal cancer occurrence and metastasis resistance.World journal of gastrointestinal oncology · 2024Review
- Targeting the EphA2 pathway: could it be the way for bone sarcomas?Cell communication and signaling : CCS · 2024Review
- Tumor-derived exosome PPP3CB induce gemcitabine resistance by regulating miR-298/STAT3 in pancreatic cancer.Heliyon · 2024Article
- HIST1H2BK predicts neoadjuvant-chemotherapy response and mediates 5-fluorouracil resistance of gastric cancer cells.Translational oncology · 2024Article
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 2 countries.
Jia FanSchool of Biological and Health Systems Engineering, Virginia G. Piper Biodesign Center for Personalized Diagnostics, The Biodesign Institute, Arizona State University, Tempe, AZ 85281, USA.
Qian WeiTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, PR China.
Eugene J KoayDivision of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.
Yang LiuSchool of Biological and Health Systems Engineering, Virginia G. Piper Biodesign Center for Personalized Diagnostics, The Biodesign Institute, Arizona State University, Tempe, AZ 85281, USA.
Bo NingCenter for Molecular Design and Biomimetics, The Biodesign Institute, Arizona State University, Tempe, AZ 85281, USA.
Paul W BernardDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, Texas 77030, USA.
Ning ZhangResearch Center of Basic Medical Sciences & Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Medical University, Tianjin 300070, PR China.
Haiyong HanMolecular Medicine Division, Translational Genomics Research Institute, Phoenix, AZ 85004, USA.
Matthew H KatzDepartment of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Zhen ZhaoDepartment of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA.
Ye HuSchool of Biological and Health Systems Engineering, Virginia G. Piper Biodesign Center for Personalized Diagnostics, The Biodesign Institute, Arizona State University, Tempe, AZ 85281, USA.
Arizona State University · USBanner - University Medical Center Tucson · USHouston Methodist · USTianjin Medical University Cancer Institute and Hospital · CNTranslational Genomics Research Institute · USWeill Cornell Medicine · US
Funding
Tissue ResourceP50CA126752 · NCI · BAYLOR COLLEGE OF MEDICINE · PI MALCOLM K. BRENNER, HELEN E HESLOP · 2007 to 2026
$51.4MNoncoding RNA Biomarkers for Noninvasive and Early Detection of Pancreatic CancerU01CA214254 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI Ajay Goel, DANIEL D VON HOFF · 2017 to 2026
$8.9MDirect quantitation of the circulating Mtb-peptidome for pediatric TB managementR01HD090927 · NICHD · TULANE UNIVERSITY OF LOUISIANA · PI Christopher J Lyon, Charles DeBeaux Mitchell · 2017 to 2026
$4.5MQuantification of Circulating Antigens for Pediatric TB Diagnosis andTreatment MonitoringR01AI122932 · NIAID · METHODIST HOSPITAL RESEARCH INSTITUTE · PI HU, TONY Y. · 2016 to 2019
$1.8MReal-time Detection of Active TB in HIV Exposed Children on CustomizedNanotrapR01AI113725 · NIAID · METHODIST HOSPITAL RESEARCH INSTITUTE · PI LABAER, JOSHUA · 2015 to 2018
$1.6MNCI NIH HHS P50 CA126752NCI NIH HHS U01 CA214254NIAID NIH HHS R01 AI113725NIAID NIH HHS R01 AI122932NICHD NIH HHS R01 HD090927
Abstract
PubMed holds no abstract for this paper.
Indexed as
Drug Resistance, NeoplasmAntineoplastic AgentsCell Line, TumorCell SurvivalDeoxycytidineExosomesGemcitabineHumansPancreatic NeoplasmsProteomeReceptor, EphA2Antineoplastic AgentsDeoxycytidineGemcitabineProteomeReceptor, EphA2Cytotoxic resistanceEphA2ExosomeGemcitabinePancreatic cancer
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.